Daily Advice Thread - All basic help or advice questions must be posted here. Investing |
- Daily Advice Thread - All basic help or advice questions must be posted here.
- Dow futures sure more than 1100 points as Pfizer, BioNtech say Covid-19 vaccine is 90% effective
- Bridgewater Loss Stuck at 18.6% in Main Fund After Model Tweaks
- Costco’s (COST) expansion into China seems to be a massive success so far?
- Invest now or volatility ahead?
- Can cannabis stocks run more post democratic win??
- Post Covid Blues?
- Is there ever a reason to buy an ETF product with a higher TER?
- What’s the feds end game?
- Why did the European markets just jump 6% up?
- Has anyone used the Gone Fishin Portfolio (formulated by Alexander Green) for asset allocation, and have they encountered success with it? I want to allocate $10k to invest in ETFs replicating this model for asset allocation.
- Are there any good paid investing platforms/apps/services for which you have a subscription ?
- How can we be so confident of long-term ETF investment performance?
- SNDL
- What degree would be most applicable towards investing?
- Options Wash Sale Rule
- Value of an Asset
- Portfolio Optimization Tool advice
- How long for a broker to convert LVGO to TDOC?
- Open Orphan - Part II
- CCL
| Daily Advice Thread - All basic help or advice questions must be posted here. Posted: 09 Nov 2020 04:16 AM PST If your question is "I have $10,000, what do I do?" or other "advice for my personal situation" questions. If you are going to ask how to invest you should include relevant information, such as the following:
Please consider consulting our FAQ first - https://www.reddit.com/r/investing/wiki/faq Be aware that these answers are just opinions of Redditors and should be used as a starting point for your research. You should strongly consider seeing a registered financial rep before making any financial decisions! [link] [comments]  |
| Dow futures sure more than 1100 points as Pfizer, BioNtech say Covid-19 vaccine is 90% effective Posted: 09 Nov 2020 03:55 AM PST WOW, today is going to be quite a day by the looks of it!! (oops - title meant to say "surge", sorry) U.S pharmaceutical giant Pfizer and German biotech firm BioNTech said their coronavirus vaccine was more than 90% effective in preventing Covid-19 among those without evidence of prior infection, according to data published Monday from their late-stage vaccine trial. It comes as drugmakers and research centers around the world scramble to deliver a safe and effective vaccine in an attempt to bring an end to the coronavirus pandemic that has claimed over 1.25 million lives worldwide. Scientists are hoping for a coronavirus vaccine that is at least 75% effective, while White House coronavirus advisor Dr. Anthony Fauci has previously said one that is 50% or 60% effective would be acceptable. Albert Bourla, chairman and CEO of Pfizer, hailed the development as a "great day for science and humanity." The results were based on the first interim efficacy analysis conducted by an external and independent Data Monitoring Committee from the phase three clinical study. The independent group of experts oversee U.S. clinical trials to ensure the safety of participants. The analysis evaluated 94 confirmed Covid-19 infections among the trial's 43,538 participants. Pfizer and BioNTech said the case split between vaccinated individuals and those who received a placebo indicated a vaccine efficacy rate of above 90% at seven days after the second dose. It means that protection from Covid-19 is achieved 28 days after the initial vaccination, which consists of a two-dose schedule. The final vaccine efficacy percentage may vary, however, as safety and additional data continues to be collected. "The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19," Pfizer's Bourla said in a statement. "We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen," Bourla continued. "With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks." Roughly 42% of the trial's participants had diverse backgrounds, Pfizer and BioNTech said, adding that there haven't been any serious safety concerns reported yet. The companies said they planned to submit for emergency use authorization to the U.S. Food and Drug Administration soon after they have two months of data, which is currently on track for the third week of November. Based on current projections, Pfizer and BioNTech expect to produce up to 50 million vaccine doses in 2020, and up to 1.3 billion doses in 2021. The companies said they plan to submit data from the full phase three trial, which began on July 27, for scientific peer-review publication. [link] [comments]  |
| Bridgewater Loss Stuck at 18.6% in Main Fund After Model Tweaks Posted: 08 Nov 2020 09:28 AM PST
[link] [comments]  |
| Costco’s (COST) expansion into China seems to be a massive success so far? Posted: 08 Nov 2020 10:32 AM PST The average Costco warehouse in western countries average around 60k subscriptions. In other Asian countries a warehouse might get around 100k subscriptions after 2 years of being open. After the Warehouse in Shanghai opened in late 2019, its subscription count grew to 250k in under 3 months. With the warehouse shutting down local traffic and being forced to close early due to the chaos that ensued on opening day. Costco plans on opening a second warehouse in Suzhou. And may grow more rapidly after they gain more experience with operating in China. "We typically open 2-3 locations in a country, and see how they operate over the first couple of years, ... We are off to a good start with our first opening last year." - Richard Galanti, CFO, "It may take a couple of years to improve efficiencies. That's one of the reasons why we generally go slow in new countries because we want to get it right from customer experience and also from the operational side," he added. With China's growing middle class and Costco's brand being extremely popular among the Chinese... It could be plausible that China will end up becoming the majority of Costco's revenue one day? Sources: https://www.google.com/amp/s/amp.cnn.com/cnn/2020/08/27/business/costco-china-intl-hnk/index.html [link] [comments]  |
| Invest now or volatility ahead? Posted: 09 Nov 2020 04:03 AM PST Hello all, So I've been planning a for a few months to invest a significant amount (£100k) into the market for a 5-10 year time horizon. Mostly in trackers and high growth investment trusts (I live in UK). Currently have invested a reasonable sum in a few shares since July, all of which are up quite a lot. However, I have I held off so far predominantly due to uncertainty over a 2nd wave sell-off / US election uncertainty. But now that uncertainty appears to have reduced, and the likelihood of a correction seems reduced, is it time to invest the bulk of money now and forget ? I certainly have missed out some solid gains, and I guess this is a perfect case of 'time in the market beats timing the market', and I should therefore just buy and forget? Please let me know what you guys are doing and would recommend. Thank you! [link] [comments]  |
| Can cannabis stocks run more post democratic win?? Posted: 08 Nov 2020 09:14 PM PST KuberSpeaks newsletter predicted cannabis stocks movement in the month of October. Great run in the Shares of marijuana producer Tilray Inc (TLRY), surging last 3 weeks. This is a classic Tilray bull flag breakout stock chart after a week of bullish consolidation. Tilray ran from $4.40 to $6.70 two-three weeks ago. This was the beginning of the election cycle move they have predicted. Over the last week, it pulled back, forming a bullish inside bar/bull flag. Now the stock is surging 10% to $6.11 by lunch time. Based on the stock chart setup, this Tilray bull flag breakout stock chart has upside to nearly $12.00/share. Hedge funds are extremely underweight marijuana stocks based on a chance of a Democratic sweep. It has happened, vice presidential candidate Kamala Harris has stated they will legalize marijuana on a federal level. If that happens, these stocks are worth double or triple where they are trading. Hedge funds need to pile in prior to the election even just on the chance that happens. Tilray has a great stock chart and a ton of upside. Others include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronus (CRON) and Aphria (APHA) What do you think?? My profits are double in last 4 weeks [link] [comments]  |
| Posted: 08 Nov 2020 07:33 AM PST I've spent a fair sum of time during my investment career researching the phenomenon of post-victory market declines. Such bear markets have occurred after many large victories, to the scale of WW2, where stocks climbed to ATHs during the war itself, yet declined sharply when the dust settled, even with no change in fundamental economic outlooks. Given the arguably even larger impact Covid has and will continue to have on the globe, and the markets gleeful reaction to the progress in fighting the virus, I can help but feel the atmosphere is of such that the decline may begin when the battle is won, as precedent has alluded. Obviously any speculation is simply a thought exercise in such instances, and the only sound advice is to cost average and hold long term, this is more a topic I'd like to discuss as a matter of curiosity. [link] [comments]  |
| Is there ever a reason to buy an ETF product with a higher TER? Posted: 09 Nov 2020 12:49 AM PST I was looking in https://www.justetf.com/de-en/find-etf.html?index=MSCI%2BWorld&groupField=none&sortField=ter&sortOrder=asc comparing different products for the MSCI World index. I see that the one with the lowest TER is Lyxor (0.12%) and the iShares is one of the highest (0.50%). I see that a lot of people around me buy iShares. I assume that sometimes the broker does not offer Lyxor and so people would buy iShares, and probably the broker gets a kickback. But it appears that a lot of times the broker offers both and people sometimes go for iShares. I was wondering if there is ever a good reason in the example above to go for the more expensive TER product (iShares) instead of Lyxor? Thank you all :) [link] [comments]  |
| Posted: 08 Nov 2020 07:39 PM PST It seems as central banks buy more of the debt and stocks the market gets more and more distorted. Won't there be a certain point during a downturn where the rich will try to sell off their assets release some of that created money which may spur on hyper inflation? I don't normally tend to be a doomer but I worry something like this will wipe out anyone who's not a multiple millionaire. For instance Japan already owns 4% of their stock market and the Swiss national bank owns 80+ billion in shares in the us stock market. [link] [comments]  |
| Why did the European markets just jump 6% up? Posted: 09 Nov 2020 04:30 AM PST WTF is happening? I looked away from my screen and then back and there was this crazy jump... I've never seen something like this. Just look at the EuroStoxx 50, for instance: https://www.google.com/search?q=eurostoxx+50 Or the CAC40: https://www.google.com/search?q=cac40 Any ideas? [link] [comments]  |
| Posted: 09 Nov 2020 04:04 AM PST Has anyone used the Gone Fishin Portfolio (formulated by Alexander Green) for asset allocation, and have they encountered success with it? I want to allocate $10k to invest in ETFs replicating this model for asset allocation. According to this model, the returns comparable to the S&P500 are lower, however this is because of exposure to bonds which are less volatile and higher yielding (especially in 2020). However in some years, this model has outperformed the S&P500. Would love to get anyone's thoughts on this model for asset allocation, and if there are any useful books people read on this topic. [link] [comments]  |
| Are there any good paid investing platforms/apps/services for which you have a subscription ? Posted: 08 Nov 2020 06:34 AM PST I am wondering about what tools you use/would recommend ? For example, is TradingView Pro worth it ? What trading services, software, apps do you pay for ? I was discussing this in the Discord and the typical answer was "what my broker provides". Would like to know if some of you have different experiences. [link] [comments]  |
| How can we be so confident of long-term ETF investment performance? Posted: 08 Nov 2020 11:36 AM PST Browsing Reddit and the internet in general, I understand that the most common (and safest) investing advice is to put most of one's capital into low costs index funds/ETFs tracking mainly the US stock market (SPY, QQQ etc...). The reasoning behind it is that the US stock market has historically always gone up in the long term. (ps. I think Warren Buffet even said in an interview) My question is: How can everyone be so sure that the US will perform well in the future, even in the long term? Are there instances of developed countries whose stock market performed poorly even in the long term? [link] [comments]  |
| Posted: 08 Nov 2020 05:56 PM PST What's everyone's thoughts on Sundial's stocks. Seen a keen interest in Cannabis stocks across the board. Meeting Thursday. Has anyone jumped on this stock yet? Seeking some advice on whether it might be an alright investment as I'm learning the ropes. [link] [comments]  |
| What degree would be most applicable towards investing? Posted: 09 Nov 2020 02:40 AM PST Hey everyone. Starting to apply to university and have a great passion for day trading. I am now starting to get interested in investing. What degree would be most applicable towards investing? Also would love to see people's feedbacks on if their degree has helped them out with investing and if they would have chosen something else. Thanks [link] [comments]  |
| Posted: 09 Nov 2020 02:05 AM PST So in August 2020 I made a bit over $15k profit from Tsla options on Robinhood, within the same month and September I bought several Tsla options but they were all sold for losses and I also bought some stock as prices were dropping. From my understanding of the wash sale rule, I cannot claim the losses due to buying the same option/stock within 30 days. However, I read the losses will be added to my basis of the replacement security. For example: Week 1 I bought XYZ option for $2,000, then I sell the shares for $1,200, thus incurring an $800 short-term loss at the end of the week. Week 2, I buy option XYZ again at $1,300. My $800 loss is disallowed, but it gets added to the basis of the replacement option. So my basis becomes $2,100 ($1,300 plus the $800 disallowed loss). At the end of the week, my options are sold at $1200. A loss again since I bought at $1300 but sold at $1200, so my total loss is now ($800 +$100=$900). Will my $900 loss be added to a new basis again if I buy more XYZ stock/option or will none of it be allowed for capital loss. If I buy XYZ stock and hold it but I also buy XYZ options around the same time, is my new $900 loss added to my cost basis of the stock or the options based on when I sell it? This is all very confusing because the stock split also occurred around the same time. I also bought options of different companies but most of them were losses as well but I did not buy them again, will these for sure count as capital losses to offset my gains? I'm still up in profit but significantly less due to all bad choices with options. Thank you in advance if you could explain it like I'm 5 with examples because this is all very confusing and I want to learn because tax season is going to be very confusing for me. [link] [comments]  |
| Posted: 08 Nov 2020 03:19 PM PST Reading through Aswath Damodaran's textbook on Valuation. I'm a bit puzzled and if someone can offer some clarification that would be appreciated. "To illustrate, assume that you have an asset in which you invested $100 million and that you expect to generate $12 million in after-tax cash flows in perpetuity. Assume further that the cost of capital on this investment is 10 percent. With a total cash flow model, the value of this asset can be estimated as follows: Value of asset = $12 million/.1 = $120 million" Damodaran, Aswath. Investment Valuation . Wiley. Kindle Edition. Why is the value $120M? Why is CF / cost of capital = value ? [link] [comments]  |
| Portfolio Optimization Tool advice Posted: 08 Nov 2020 09:12 PM PST Hi All, I built (80%) a tool for stock portfolio optimization in Python.I'm looking for advice as to what additional analyses or functions / features I should add. The objective is to automate the steps of my decision making on my annual audit of my Vanguard stock portfolio. Simply put, the program:
My questions:
I am not looking for compliments or any kind of monetization. I only am interested in suggestions for improvement. Images from the prototype program: https://imagizer.imageshack.com/img924/696/1By1HN.png https://imagizer.imageshack.com/img922/5702/aXjqwm.png https://imagizer.imageshack.com/img924/5436/97ad0H.png https://imagizer.imageshack.com/img922/8756/A3Tf6i.png https://imagizer.imageshack.com/img924/9026/EDTU5V.png [link] [comments]  |
| How long for a broker to convert LVGO to TDOC? Posted: 08 Nov 2020 07:17 PM PST I understand it probably varies from broker to broker, but roughly how long would it take for LVGO shares to become TDOC? I already received the cash part of the merger in my broker account, but my LVGO shares are still sitting there and I am just wondering when to approximately expect those to be converted to TDOC. Anyone know how long such an action would typically take? Cheers [link] [comments]  |
| Posted: 08 Nov 2020 10:34 PM PST In my original cover piece of Open Orphan (ORPH) on the 30th October 2020 I indicated the company is not a one trick pony play on covid-19. The company has a portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. East London Queen Mary Bio-Enterprise facility is now close to fully booked until the end of 2021. It is the world leader in testing antivirals and vaccines. What makes the company so attractive to the large pharmaceuticals and government agencies is the fact it has the world's largest database for infectious diceases. However, it must be said the Covid-19 part of the business, namely the world's first company to take part in human for the Covid-19 challenge vaccine trial appears to be an area the retail investors is chasing the money. But wait, there is more to Open Orphans as I will explain a little later in the follow-up. It is worth noting no more fundraisers' are expected, the last raise was for £12m in May, of which it still had m of this last week, giving at total of £21.5m plus £10m received on Monday from the UK government, plus £2.5m announced on the 5th November - assuming I have not misheard Cathal's strong Irish accent the company should have somewhere in the region of £34m of cash. With more £multi million contract wins anticipated it is likely Open Orphan will offer special dividends to shareholders. I don't believe there are any dilutive share options due in the future to the board. I think Cathal referred to these type of options being granted as theft. I'm not sure I agree with this unless the board are amply renumberated. Thus no liefestyle pay packets for the board, Cathal is on £140,000 and he is the highest paid member of a well run board. Due to the company's specialist facilities and database which has positioned the company ahead of any other company in the world, which meaning it has become the goto human vaccine challenge company, thus well positioned to become rapid cash-cow, with estimates of £4m worth of contracts each month in Q3, with Q4 looking to accelerate the income stream's which could expand at warp speed if the company has as some of us suspect the unnamed US biotechnology company now partnered by their hVIVO arm are involved with Trumps Warp Speed Project. Operation Warp Speed was introduced in early April 2020, after a round-table meeting with Trump, Pence and industry executives at the White House on March 2. It will promote mass production of multiple vaccines based on preliminary evidence allowing for faster distribution if clinical trials confirm one of the vaccines is safe and effective. As part of the funding the US government has allocated $10 billion for Operation Warp Speed through the Coronavirus Aid, Relief, and Economic Security (CARES) Act, with $6.5 billion designated by Congress for countermeasure development through BARDA, along with $3 billion for NIH research. For the moment we do not know if Open Orphan is part of this project - For now, Cathal Friel is keeping a tight lip. Imagine how exciting very exciting this project could be for us? Probable M&A Activity (it is no secrete) I will focus on Imutex as this has the most potential in terms of value for shareholders, which I believe will be returned in the form of a dividend. Open Orphan has a 49% owned interest in Imutex - picked up for beans. Earlier this year its hVIVO unit reported successful phase IIb trial of a potential flu vaccine for its FLU-v. This has resulted in a joint-venture peer-reviewed article written in a scientific journal. The data from FLU-v 004 challenge study underlined its ability to reduce mild-to-moderate symptoms of the illness. The publication of the results in the periodical ''npj Vaccines'' follows results from a separate field assessment of the drug, which revealed "cellular and humoral immunogenicity" from a single dose of adjuvanted FLU-v. Meaning the vaccine immediately provoked an immune response. If as expected Imutex meetings with FDA regulators in the USA ahead of further trials, this should pique interest from M&A suitors. Open Orphan chief executive Trevor Phillips: "Progression to larger phase III studies with FLU-v can further describe the cellular immune response and evaluate how the vaccine interacts with influenza disease," Open Orphan chief executive Trevor Phillips. CEC Cathal Friel: "The need for better, more broadly protective vaccines against influenza is a high priority worldwide, and few new vaccines have demonstrated efficacy in humans as seen in the results of the challenge study for FLU-v 004. "This is the first universal influenza vaccine that has shown this protection from influenza and reduction of symptoms in late-stage studies and together with the highly statistical immune results reported in a peer review article means that the risk of failure in a phase III setting is greatly reduced compared with entering into phase III studies with no efficacy data." No doubt revenues are anticipated to grow at pace in the coming months as bed capacity/occupancy increases, if not sooner...probably sooner because the CEO. Cathal Friel is a man on a mission to gets things done. I am sure we all expect news on this front from Holland and the USA soon. All of this I believe to be just c90 per cent of the business if I understand Cathal Friel. It is fair to say Open Orphan has struck gold with its acquisition of hVIVO shortly followed by the acquisition of CHIMagent for a nominal fee. Leaving aside the relatively poor performance before Open Orphan opportunistic, or should I say insightful vision. Along with VENN, these little beauties have transformed the company in a matter of a few months, moreover, have not proved to be a cash drain on the company, but have fitted into a brilliant strategy almost seamlessly and the bonus, that they are already producing a lot of cash with much more to come. Which means Q4 group profitability I believe to be at a NET cash level. Smart Us of The World Largest Infection Dicease Database I am really excited for the monetisation of the world's largest infectious dicease database. The excitement is centered around utilising the data in everyday consumable wearables. Previous management did not seem to understand the value they had until Cathal Friel arrived a shrewder Irishman, and these fellas are not known for missing much when it comes to turning muck into brass. I am not sure I can call infectious diceased much, unpleasant perhaps! No matter, they have considerable value as we are already witnessing, yet Cathal appears to have found another way to unlock more value in a way I find even more exciting. Let's face it, we will need to learn to live with Covid-19 for some time to come, and everyday affordable wearables could help the world live with infectious diceased that make us much more aware of them. The talk coming from Open Orphan (not just BB gossip), is Apple and Amazon, plus others, are seeking to use the database for wearable devices, smartwatches, health monitor devices, etc. These are often premium devices, especially if you are Apple or Samsung smartwatches brands. So, what is the market size for smart devices? As investors we shouldn't allow Apple's cash pile reported to be $1900bn to excite us too much - Apple didn't amass that cashpile by giving away money to smaller companies as a charitable donation, these companies a ruthless as I am sure their Chinese workforce would profess to their collective dismay. That said, if anyone thinks Cathal, et al at the company do not realise its worth and do not know how to pitch one corporate off against another are fools. Not many Open Orphan investors strike me as fools. Global Smart Devices Market - Huge and Growing Fast The global wearable medical device market size was valued at USD 13.0bn in 2019 and is expected to witness a CAGR of 27.9% over the forecast period. The growth of industries such as home healthcare and remote patient monitoring devices is anticipated to positively influence the demand for wearable devices. In addition, increasing consumer focus on fitness and efforts toward leading a healthy lifestyle are expected to positively fuel the product demand. More from the report here. The Global Smart Healthcare Market size stood at US$ 141bn in 2019 and is expected to grow at 14.5% through 2030. Smart Healthcare is technology integrated diagnostic tool used for treating patients and improving the quality of life using e-health, m-health and ambient assisted living services. Rising government initiatives for the digitization of healthcare infrastructure are driving the growth of the smart healthcare market. More from the report here. The number of connected wearable devices worldwide has more than doubled in the space of three years, increasing from 325m in 2016 to 722m in 2019. The number of devices is forecast to reach more than one billion by 2022. Two important factors to the growth within the wearable devices market is primarily being powered by sales of smartwatches – shipments of smartwatches worldwide are forecast to surpass 100m in 2020. Apple, who unveiled their first smartwatch in 2015, currently dominate the smartwatch market and have held a share of around 45% since 2018. Another reason for the growth of the wearables market is the rise in popularity of hearable devices. Also referred to as earwear or ear-worn devices, this category is expected to soar over the next few years with shipments of devices forecast to increase by 45% to 105m units by 2023.
Any search you chose to do for smartwatches, or health monitoring devices will vary from the cheap and nasty, to the premium expensive kind. What is important as far as we are concerned, and Open Orphan of course, is the fact the company has a very lucrative database of infectious diceases. Some of the world's largest companies are seeking to supplant in their wearable smart devices. While these devices may have been around for a while, and in some cases become a short-term fad for the post-Christmas fitness bunny, I think, as do Apple and Amazon, probably others, a new more important market has just opened up, one that has the potential to save lives as well as monitor health and wellbeing on an all new level previously only health care professionals had access too. As I understand it. The idea is to license Open Orphan data to smart device manufacturer(s). These devices will have the ability to instantly warn the consumer they have contracted symptoms of an infectious dicease, which will have a variety of alert levels related to the disease offering specific advice, like self isolate, off you pop to hospital, etc. The £multi million question must be who with? One option is to a global leader as first mover advantage on an exclusivity period - naturally this option would yield significant margins to Open Orphan by virtue of the market it would grab ahead of any other adopter because this would of course add significant value in today's pandemic environments. Then the second highest bidder? Or multiple companies and or government agencies. The moral standpoint I have is one of ethics and morality. (I make no apologies for my Master Mason and Christian beliefs) To my mind I think such ground-breaking technology should be made as widely available as possible because the alert system is lifesaving, track and traceability (IF AN OPTION) could become a problem if governments do not put financial safety nets in place for people contracting Covid -19 or ave some symptoms that require isolation, this being the only real negative I see for such devices as this would reduce its effectiveness. The other question is the pricing for such data access and alerts in real time - will this price the ordinary mid to low salary consumers be priced out of the market, thus reduce the effectiveness if it were not made available more widespread at affordable pricing levels? This must be a factor for opening up the world economy again...yes, it really has the potential to be this important. What price could be put on this new ground-breaking market to Open Orphan? Surely global governments have more buying power than any global Apple, Amazon type business. Hell fire, do they deserve this opportunity! Thank you for reading. Please share the links. Elric Lloyd-Langton [link] [comments]  |
| Posted: 09 Nov 2020 12:59 AM PST Not a pro whatsoever, not a genius at all, but I think we're going to see another dip on the cruise lines this week. I will be buying MORE CCL and holding long. I don't believe this company is going away, they will struggle yes, but will come back strong post Covid. Like Warren Buffett says "when the stock market goes down, that's a good day." Good luck to everybody, I hope you all get rich. [link] [comments]  |
| You are subscribed to email updates from Lose money with friends!. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment